Prevention of chemotherapy-induced alopecia using an effective scalp cooling system.

Alopecia is a distressing side-effect of cancer treatment. Taxanes (TX), anthracyclines (ANR) and etoposide (ET) have been consistently associated with significant alopecia. We studied an effective scalp cooling system, the Penguin Cold Cap system, for the prevention of chemotherapy-induced alopecia in 70 patients receiving chemotherapy, including one of the following major alopecia-causing agents: Group A, TX-based regimes (without ANR); Group B, TX+ANR; Group C, ANR-based regimes (without TX); Group D, ET-based regimes. Protection from hair loss was achieved by maintaining scalp temperatures below 15 degrees C before, during and after chemotherapy by frequent changing of the caps. Assessment was carried out using a grading system from 0 to 4. Grades 0-2 were considered as satisfactory hair protection, whilst Grades 3-4 were considered failures. 57 patients were evaluable for assessment. An overall 81% protection was achieved. In groups C and D 11 of 12 patients (92%) had no alopecia, whilst 30 of 34 patients (88%) treated with taxanes had adequate hair protection. In Group B, 4 of 11 patients (36%) had adequate hair protection. The system was well tolerated and is a very effective method for protection from hair loss caused by TX, ANR and ET. Our results are comparable with and, in most cases, better than those reported in other studies using various alopecia preventive methods.

[1]  D. Geddes,et al.  SCALP COOLING BY THERMOCIRCULATOR , 1982, The Lancet.

[2]  J. Dean,et al.  Prevention of doxorubicin-induced hair loss with scalp hypothermia. , 1979, The New England journal of medicine.

[3]  R. P. Gregory,et al.  Prevention of doxorubicin-induced alopedia by scalp hypothermia: relation to degree of cooling. , 1982, British medical journal.

[4]  M. van Glabbeke,et al.  Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  E. Greenwald CHAPTER I – PHARMACOLOGY OF CANCER CHEMOTHERAPY , 1967 .

[6]  A. Caraceni,et al.  Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  B. Kaufman,et al.  Bone marrow-sparing and prevention of alopecia by AS101 in non-small-cell lung cancer patients treated with carboplatin and etoposide. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  R. Motzer,et al.  Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Neuberg,et al.  Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience. , 1994, Seminars in oncology.

[10]  R. Buchanan,et al.  Failure of scalp hypothermia to prevent hair loss when cyclophosphamide is added to doxorubicin and vincristine. , 1985, Cancer treatment reports.

[11]  G. Giaccone,et al.  Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Zimm,et al.  The use of scalp hypothermia in the prevention of doxorubicin‐induced hair loss , 1984, Cancer.

[13]  L. Friberg,et al.  Frontal subcutaneous blood flow, and epi- and subcutaneous temperatures during scalp cooling in normal man. , 1985, Scandinavian journal of clinical and laboratory investigation.

[14]  G. Bonadonna,et al.  ABVD in the treatment of Hodgkin's disease. , 1992, Seminars in oncology.

[15]  B. Cline Prevention of chemotherapy‐induced alopecia: A review of the literature , 1984, Cancer nursing.

[16]  E. Bessa,et al.  Effectiveness of cold cap in the prevention of docetaxel-induced alopecia. , 1997, European journal of cancer.

[17]  L. Norton,et al.  Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.

[18]  S. Carter Adriamycin-a review. , 1975, Journal of the National Cancer Institute.

[19]  J. Gehl,et al.  Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer. , 1996, Seminars in oncology.

[20]  D G Lowe,et al.  A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Breed Wp,et al.  Scalp cooling by cold air for the prevention of chemotherapy-induced alopecia. , 1990 .

[22]  W. Wilson,et al.  Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  G. Hortobagyi,et al.  A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Hussein Chemotherapy-Induced Alopecia: New Developments , 1993, Southern medical journal.

[25]  O. J. Repelaer van Driel,et al.  Scalp cooling has no place in the prevention of alopecia in adjuvant chemotherapy for breast cancer. , 1994, European journal of cancer.

[26]  N. Pavlidis,et al.  A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  S K Carter,et al.  Adriamycin. A new anticancer drug with significant clinical activity. , 1974, Annals of internal medicine.

[28]  J. Kievit,et al.  Effect of peri-operative chemotherapy on the quality of life of patients with early breast cancer. , 1990, European journal of cancer.